Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5272099
Max Phase: Preclinical
Molecular Formula: C38H65N15O9S2
Molecular Weight: 940.17
Associated Items:
ID: ALA5272099
Max Phase: Preclinical
Molecular Formula: C38H65N15O9S2
Molecular Weight: 940.17
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CCSSC[C@@H](C(N)=O)NC1=O
Standard InChI: InChI=1S/C38H65N15O9S2/c39-28(54)12-10-24(34(60)52-26(18-20-6-2-1-3-7-20)36(62)51-25-14-17-63-64-19-27(30(40)56)53-35(25)61)50-32(58)22(9-5-16-46-38(43)44)48-31(57)21(8-4-15-45-37(41)42)49-33(59)23-11-13-29(55)47-23/h20-27H,1-19H2,(H2,39,54)(H2,40,56)(H,47,55)(H,48,57)(H,49,59)(H,50,58)(H,51,62)(H,52,60)(H,53,61)(H4,41,42,45)(H4,43,44,46)/t21-,22-,23+,24+,25+,26+,27+/m1/s1
Standard InChI Key: GMORKTHGQGYYGH-KZPPUNKBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 940.17 | Molecular Weight (Monoisotopic): 939.4531 | AlogP: -3.79 | #Rotatable Bonds: 24 |
Polar Surface Area: 413.68 | Molecular Species: BASE | HBA: 13 | HBD: 15 |
#RO5 Violations: 3 | HBA (Lipinski): 24 | HBD (Lipinski): 19 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 10.69 | CX Basic pKa: 11.79 | CX LogP: -6.64 | CX LogD: -10.50 |
Aromatic Rings: 0 | Heavy Atoms: 64 | QED Weighted: 0.02 | Np Likeness Score: 0.24 |
1. Brust A, Croker DE, Colless B, Ragnarsson L, Andersson Å, Jain K, Garcia-Caraballo S, Castro J, Brierley SM, Alewood PF, Lewis RJ.. (2016) Conopeptide-Derived κ-Opioid Agonists (Conorphins): Potent, Selective, and Metabolic Stable Dynorphin A Mimetics with Antinociceptive Properties., 59 (6): [PMID:26859603] [10.1021/acs.jmedchem.5b00911] |
Source(1):